临床试验/NCT00488189

NCT00488189已完成4 期

Association of Antibiotic Utilization Measures and Control of Extended-Spectrum β-Lactamases (ESBLs) Producing Bacteria

Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 134 人开始时间: 2007年5月最近更新: 2011年4月15日

适应症

干预措施

试验速览

阶段: 4 期
状态: 已完成
发起方
入组人数: 134
主要终点: 1. The acquisition rate of ESBL producing E. coli or K. Pneumoniae at the end of phase I (pre-intervention) and phase II (last 3 months of intervention phase)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

This is an antibiotic intervention study to determine the value of using piperacillin/tazobactam in reducing the cases of ESBL producing E. coli or K. pneumoniae colonization and infection.

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Single Group
主要目的: Health Services Research
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•All patients admitted or transferred to ICU/Pulmonary units
•Patients of either sex, 18 years of age or older

排除标准

•Patients who stay in units less than 48 hours will not be enrolled.

研究组 & 干预措施

2

Active Comparator

use pipercill/tazobact to replace 3rd generation cephalosporin and collect rectal swab

干预措施: Tazocin (pipercillin/tazobactam) (Drug)

结局指标

主要结局

1. The acquisition rate of ESBL producing E. coli or K. Pneumoniae at the end of phase I (pre-intervention) and phase II (last 3 months of intervention phase)

时间窗: 9 months

次要结局

The infection rate due to ESBL producing E. coli or K. pnumoniae at the end of phase I (pre-intervention) and phase II (last 3 months of intervention phase)(9 months)

研究者

发起方

Wyeth is now a wholly owned subsidiary of Pfizer

申办方类型

Industry

相似试验

已完成

4 期

Tazocin Intervention StudyBacterial Infections

NCT00478855Wyeth is now a wholly owned subsidiary of Pfizer500

已完成

不适用

Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology UnitsGram-Positive Bacterial InfectionsEscherichia Coli InfectionsKlebsiella Infections

NCT00167999Wyeth is now a wholly owned subsidiary of Pfizer200

已完成

4 期

Study Evaluating Antibiotic Utilization Measures and Control of Extended-Spectrum-Lactamases (ESBLs)Bacterial Infection

NCT00254696Wyeth is now a wholly owned subsidiary of Pfizer710

已完成

不适用

Study Evaluating the Association of Antibiotic Measures and Control of Bacterial ResistanceBacterial Infections

NCT01788449Wyeth is now a wholly owned subsidiary of Pfizer335

已完成

3 期

Piperacillin-Tazobactam Continuous Versus Intermittent Infusion for Pseudomonas AeruginosaPseudomonas Aeruginosa Infection

NCT01577368Fundación Pública Andaluza para la gestión de la Investigación en Sevilla76